We dig only mechanically without using mines separating the material with higher content of zeolite clinoptilolite (volcanic mineral). Each batch is checked after a first thermal activation of the material. We control the structure and mineralogical properties ensuring the presence of all ions and components of the structure. 

It is developed by a team of engineers under the guidance of the inventor Jakob Hraschan. Patent WO / 2018/100178. PMA technology (PANACEO MICRO ACTIVATION) is a micronization technology that uses mills with counter-rotating blades; these rotate with a thrust of 2400 km / h. The contrary air flows created by the two rotors cause the self-collision of the particles, which take place at 3/4000 collisions per second and at temperatures of approx. 400 °. FILM Activation helps to increase the surface charge of the individual particles and to increase the cation exchange surface. (after two activations we have up to 4000 square meters per gram - mathematical calculation of Prof. Dr. Rudolf Taschner of the University of Vienna).

The powders are filtered by devices that detect their size and are finally analyzed with spectrophotometry to confirm that the original mineral composition is not altered. Chemical and bacteriological analyzes follow. We are subjected to continuous verification of updates to regulations and practices. Our technical dossier on PMA-zeolite is the most advanced and complete in EU.

They are studies funded at hospitals and universities. The areas in which we do research are: gastroenterology, neurodegeneration, oncology and bone physiology. We currently have several studies under way in Italy, Austria and Germany. Our scientific committee coordinated by Prof. Kresimir Pavelic performs continuous audits and studies, followed by publications.

It is the only zeolite clinoptilolite to have performed a complete study on toxicity, acute, sub-chronic and chronic. (Prof. K. Pavelic). Because the activated molecule is very different from the starting mineral. And we constantly study the conditions of mineral intake. Being an aluminosilicate, that is composed of aluminum, silicon and oxygen, a study on the release of pollutants is particularly necessary.

The patents on PMA-zeolite on polyneuropathy, neuroprotection, bone diseases, lactate reduction are the following -N ° WO2013098049 -N ° EP2600840 -N ° WO2008077174 -N ° EP1938825 -N ° EP1480659

The CE mark must appear followed by a number that corresponds to a controlling body. If only the CE marking appears, these are devices that can not remain in the body for more than 60 minutes or, more often, of medical I-phase devices for topical use. 

In EU, PMA-zeolite is used for Class IIa medical devices for oral use. Council Directive 90/385 / EEC and Council Directive 93/42 / EEC constitute the Union regulatory framework for Class IIa or IIb medical devices. REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on medical devices, amending Directive 2001/83 / EC, Regulation (EC) 178/2002 and the regulation (CE) n. 1223/2009 and repealing Council Directives 90/385 / EEC and 93/42 / EEC.